Home Cart Sign in  
Chemical Structure| 1672662-14-4 Chemical Structure| 1672662-14-4

Structure of PT2399
CAS No.: 1672662-14-4

Chemical Structure| 1672662-14-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PT2399 is a potent HIF-2α antagonist that directly binds to the HIF-2α PAS B domain, suitable for treating tumors related to HIF-2α.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PT2399

CAS No. :1672662-14-4
Formula : C17H10F5NO4S
M.W : 419.32
SMILES Code : O[C@@H]1C(F)(F)CC2=C(OC3=CC(C#N)=CC(F)=C3)C=CC(S(=O)(C(F)F)=O)=C12
MDL No. :MFCD32062659

Safety of PT2399

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of PT2399

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
UMRC2 2 µM 2 to 5 weeks Evaluate the effect of PT2399 on the growth of UMRC2 cells in soft agar, results showed PT2399 did not significantly suppress the growth of UMRC2 cells. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
CAKI2 2 µM 2 to 5 weeks Evaluate the effect of PT2399 on the growth of CAKI2 cells in soft agar, results showed PT2399 did not significantly suppress the growth of CAKI2 cells. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
769-P 2 µM 2 to 5 weeks Evaluate the effect of PT2399 on the growth of 769-P cells in soft agar, results showed PT2399 did not significantly suppress the growth of 769-P cells. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
OSRC2 2 µM 2 to 5 weeks Evaluate the effect of PT2399 on the growth of OSRC2 cells in soft agar, results showed PT2399 suppressed the growth of OSRC2 cells. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
786-O 2 µM 2 to 5 weeks Evaluate the effect of PT2399 on the growth of 786-O cells in soft agar, results showed PT2399 suppressed the growth of 786-O cells. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
C4-2 cells 50 µM 24 hours PT2399 significantly decreased HSD3B1 expression in HR cells and inhibited nuclear localization of HIF2α and its binding to ARNT. Cancer Res. 2022 Jul 5;82(13):2417-2430
LNCaP cells 50 µM 24 hours PT2399 significantly decreased HSD3B1 expression in HR cells and inhibited nuclear localization of HIF2α and its binding to ARNT. Cancer Res. 2022 Jul 5;82(13):2417-2430
769-P cells 2 µM 48 hours PT2399 failed to down-regulate cyclin D1 abundance in 769-P cells. Sci Signal. 2019 Oct 1;12(601):eaay0482
UMRC-2 cells 2 µM 48 hours PT2399 failed to down-regulate cyclin D1 abundance in UMRC-2 cells. Sci Signal. 2019 Oct 1;12(601):eaay0482
A498 cells 2 µM 48 hours PT2399 had variable effects on basal cyclin D1 mRNA and protein abundance in the A498 cells. Sci Signal. 2019 Oct 1;12(601):eaay0482
786-O cells 2 µM 48 hours PT2399 monotherapy did not cause a statistically significant increase in the VHL-Tdtomato:EV-GFP ratio, consistent with earlier studies showing that 786-O cells tolerate the loss of HIF-2 α in short-term cultures under high serum conditions. Sci Signal. 2019 Oct 1;12(601):eaay0482

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Renal cell carcinoma tumorgraft model Oral gavage 100 mg/kg Every 12 hours for approximately 28 days To evaluate the antitumor effects of PT2399 in a renal cell carcinoma tumorgraft model. Results showed PT2399 suppressed tumorigenesis in 56% of the lines and was more active than sunitinib. Nature. 2016 Nov 3;539(7627):112-117
Nude mice 786-O cell orthotopic xenografts Oral gavage 20 mg/kg Daily for 28 days PT2399 monotherapy, as expected, suppressed 786-O cell tumor growth, with a trend toward greater suppression with the combination with palbociclib. Sci Signal. 2019 Oct 1;12(601):eaay0482
Mice Adenomyosis mouse model Oral gavage 30 mg/kg Twice daily for 2 days Inhibited HIF-2α expression and increased Hoxa10 and Hoxa11 expression Reprod Biol Endocrinol. 2021 Jan 8;19(1):7
Mice Epas1S305M/S305M knock-in mice Oral gavage 30 mg/kg Twice daily for 8 weeks PT2399 suppressed HIF-2α target gene expression in wild-type mice, ameliorated high-fat diet-induced obesity and metabolic dysfunction, but had no effect in mutant mice. Proc Natl Acad Sci U S A. 2018 Dec 26;115(52):13240-13245
Female Ncr nude mice 786-O-Fluc cell orthotopic xenograft model Oral gavage 30 mg/kg Once daily for 28 days Evaluate the effect of PT2399 on the growth of 786-O-Fluc cell xenografts, results showed PT2399 significantly inhibited tumor growth and reduced Cyclin D1 and Ki67 expression. Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119
Mice (C57Bl/6J background) Wild-type mice and HIF-2α conditional knockout mice Oral gavage 50 mg/kg Twice daily for 5 consecutive days followed by a 2-day washout period, total 14 days PT2399 treatment ameliorated radiation-induced bone loss but resulted in reduced red blood cell (RBC) counts and hemoglobin (HGB) amounts, indicating an anemic side effect. Sci Transl Med. 2023 Nov 29;15(724):eabo5217
C57BL/6 mice Subcutaneous and orthotopic pancreatic cancer models with KPC cells Oral gavage 50 mg/kg 5 days per week, twice daily, for 2-3 weeks To evaluate the therapeutic effect of PT2399 combined with immune checkpoint blockade on pancreatic cancer. Results showed that PT2399 combined with αCTLA4 significantly slowed tumor growth and improved survival. Gastroenterology. 2022 Jun;162(7):2018-2031
Mice Vhl/Trp53/Rb1 mutant mouse model Oral gavage 50 mg/kg Twice daily for 14 days Evaluating the therapeutic effects of PT2399 in a HIF-2α inhibitor-resistant mouse ccRCC model, showing no significant effect on tumor growth Cancers (Basel). 2021 Sep 25;13(19):4801
Mice 786-O and OSRC2 orthotopic xenografts Oral gavage 30 mg/kg Daily for 28 days Assess the suppression of tumor growth by PT2399 Proc Natl Acad Sci U S A. 2022 Apr 5;119(14):e2120403119

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.92mL

2.38mL

1.19mL

23.85mL

4.77mL

2.38mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories